How Much Weight Will I Lose with Wegovy?

Last reviewed: June 19, 2026

Last updated: June 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy, the brand-name version of semaglutide, has shown remarkable effectiveness in clinical studies, with participants losing significantly more weight than those taking placebo. However, the amount of weight you lose depends on several factors including your starting weight, dose escalation, diet, exercise, and your unique genetic response to GLP-1 signaling. PlexusDx helps you understand your personalized weight loss potential through precision testing and customized semaglutide protocols.

Average Semaglutide Weight Loss Results from Clinical Trials

The landmark STEP trials, which tested semaglutide for weight management, documented that patients achieved an average weight loss of 15% of their body weight when using the 2.4 mg maintenance dose. In comparison, participants receiving placebo lost only 2.4% of their body weight on average. These results were measured over 68 weeks of continuous treatment, establishing semaglutide as one of the most effective weight loss medications available.

Weight loss with semaglutide typically follows a pattern: steady reduction over the first 6–12 months as your dose increases, followed by stabilization or gradual continued loss in months 2–3 of treatment. Patients starting at lower doses experience slower initial weight loss, but this approach reduces side effects and allows your body to adapt to the medication. Most people reach their maximum weight loss effect by month 5 or 6 of consistent use at their maintenance dose.

How Your Genetics Influence Semaglutide Weight Loss Outcomes

The PlexusDx Precision Peptide Genetic Test analyzes FTO (rs9939609) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Understanding your genetic profile allows PlexusDx providers to personalize your treatment approach from day one, potentially accelerating weight loss and improving long-term adherence. Patients with favorable genetic markers for GLP-1 sensitivity often see results at lower doses, while others may benefit from higher maintenance doses or dual-compound protocols like GLP-Squared Injection. The Precision Peptide Genetic Test is available for $298, helping you optimize your therapy based on science, not guesswork.

Factors That Determine Your Personal Weight Loss Success

Individual weight loss on semaglutide ranges from 5% to over 22% of body weight, reflecting differences in adherence, baseline health status, and metabolic capacity. Your starting weight, age, insulin resistance level, and consistency with medication injections all influence final outcomes. Additionally, lifestyle factors—including dietary choices, physical activity frequency, and sleep quality—amplify or reduce the medication's effectiveness in your body.

Dose escalation plays a significant role in achieving maximum weight loss. Semaglutide is typically started at 0.25 mg weekly and increased gradually to 2.4 mg weekly over 16–20 weeks. Patients who complete the full dose escalation schedule and remain at maintenance dose consistently achieve better results than those who skip doses or stop early. PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan with the pricing guarantee that your dose may go up, but your price won't—making consistent, long-term treatment affordable.

Comparing Semaglutide to Other Weight Loss Medications and Protocols

When compared to older weight loss medications like phentermine or orlistat, semaglutide produces substantially greater weight loss—typically 3–5 times more effective. Tirzepatide, a newer dual GIP/GLP-1 receptor agonist, shows even stronger results in some patient populations, with average weight losses reaching 22% in SURMOUNT trials. PlexusDx offers both compounded semaglutide injection ($189/mo) and tirzepatide injection ($289/mo), plus combination protocols like GLP-Squared Injection for patients seeking enhanced outcomes.

Oral formulations of both semaglutide ($289/mo) and tirzepatide ($279/mo) provide convenience for patients who prefer not to inject, though they typically achieve slightly less weight loss due to lower bioavailability. For patients seeking a gentler entry point, the Microdose GLP-1 Protocol at $129/mo flat rate offers early-stage weight loss and metabolic benefits. PlexusDx serves all 50 states with no insurance requirement, making personalized semaglutide therapy accessible regardless of your coverage status.

Timeline: When to Expect Weight Loss Results with Semaglutide

Most patients notice initial appetite suppression and modest weight loss (2–4 pounds) within the first 2–3 weeks of starting semaglutide, even at the starting dose of 0.25 mg. By week 8–12, as your dose escalates to 0.5 mg, more substantial loss (5–10 pounds total) typically becomes evident. Between months 3–6, during the dose escalation to 1.7 mg and final maintenance dose of 2.4 mg, weight loss accelerates and often reaches 15–20% of starting weight by month 6.

Plateaus are normal and expected—many patients experience slower weight loss or temporary stabilization around months 7–9, then resume losing weight or maintain their new weight indefinitely. Long-term studies show that semaglutide's effects persist as long as you continue the medication; discontinuing treatment often leads to gradual weight regain. PlexusDx providers help patients plan for sustained results by establishing realistic timelines and adjusting protocols based on your individual response curve and genetic predictors.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How long does it take to see weight loss results on Wegovy?

Most patients see initial appetite reduction within 1–3 weeks and noticeable weight loss (2–4 pounds) by 4 weeks. Significant results (10+ pounds) typically appear by month 2–3 as your dose escalates, with maximum weight loss achieved around month 5–6 at maintenance dosing. Timeline varies based on your genetic response profile.

Is semaglutide from PlexusDx as effective as brand-name Wegovy?

PlexusDx semaglutide is compounded by licensed 503A pharmacies using the same active ingredient and purity standards as Wegovy, delivering equivalent clinical outcomes. Compounded semaglutide is $189/mo month-to-monthnth with no insurance required—far more affordable than brand Wegovy while maintaining identical effectiveness for weight loss and metabolic benefits.

What happens to weight loss if I stop taking semaglutide?

Studies show that weight regain begins within weeks after discontinuing semaglutide, with many patients returning to their starting weight within 12 months. The medication works best as a long-term therapy; PlexusDx offers sustainable pricing tiers and HSA/FSA eligibility to support ongoing treatment without financial burden.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (FTO (rs9939609)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.